Evotec loses research chief and Evotec stock gains 2.36 percent

Published on 10/06/2026 at 09:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue fell to EUR 300.10 million, down 19.20 percent year over year. Evotec stock costs EUR 3.04 on October 6, 2026 versus EUR 2.97.

Bunte Pop-Art-Comic-Illustration eines Wissenschaftlers mit leuchtendem Reagenzglas im Labor — Pop-Art-Comic-Szene mit Wissenschaftler und Reagenzglas symbolisiert lebendig die Forschungswelt von Evotec SE, ISIN DE0005664809, Illustration mit AI erstellt.

Evotec's research chief Cord Dohrmann left the company by mutual agreement on September 30, 2026, while Evotec stock was trading at EUR 3.04 at Lang & Schwarz on October 6, 2026 at 9:46 a.m. CEST, up 2.36 percent versus the prior close of EUR 2.97. FinanzNachrichten reported the departure as part of the company's broader strategic restructuring.

Leadership change meets weak numbers

The leadership change arrives against a difficult first half. According to Stock-World on September 8, 2026, Evotec generated EUR 300.10 million in revenue in the first half of 2026, a 19.20 percent decline from the prior-year period. Adjusted EBITDA fell to negative EUR 42.70 million from negative EUR 1.90 million.

The contrast within the business is important. Discovery, Development and Product Delivery increased net revenue by 28.00 percent in the first half of 2026, even as group revenue contracted, according to the same report. That split leaves investors watching whether stronger activity in selected operations can offset weaker conversion elsewhere.

Guidance sets the financial hurdle

Evotec's full-year 2026 outlook calls for revenue of EUR 570.00 million to EUR 610.00 million and adjusted EBITDA of negative EUR 70.00 million to negative EUR 105.00 million. The earlier revenue range was EUR 700.00 million to EUR 780.00 million, making the revised range materially lower on the company's own stated comparison.

The cost program remains the central operating test. IT Boltwise reported on October 5, 2026 that the Horizon program targets EUR 75.00 million in annual savings by the end of 2027. The next results release is scheduled for November 5, 2026, when the company can show whether the restructuring is translating into measurable progress.

Analyst target stays above the quote

Berenberg kept its Hold rating and EUR 3.60 price target after a discussion with Chief Executive Christian Wojczewski, according to FinanzNachrichten on September 25, 2026. The analyst cited commercial realignment and delayed milestones as factors limiting visibility on revenue development.

At EUR 3.04, the Lang & Schwarz price sits EUR 0.56 below that target, or 15.56 percent below EUR 3.60. The comparison makes the November reporting date significant for the stock's next valuation debate, while the current quote remains 2.36 percent above its prior close.

Evotec stock trades higher in morning session

Evotec stock was trading at EUR 3.04 at Lang & Schwarz on October 6, 2026 at 9:46 a.m. CEST, up 2.36 percent versus the Lang & Schwarz prior close of EUR 2.97. The further course of trading is shown by the continuously updated real-time quote of Evotec stock.